IMPORTANCE Walking impairment, a common clinical manifestation of multiple sclerosis (MS), is often measured in clinical practice and clinical trials using the Timed 25-Foot Walk (T25-FW). 
M ultiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system that often leads to accumulation of irreversible disability. 1 Estimates of patients with MS who experience walking impairment as the disease progresses range from 60% to more than 90%. 2 The cause of walking impairment is multifactorial, with contributions from lower-limb weakness and incoordination, spasticity, sensory loss, imbalance, and fatigue. 3 Walking impairment can have a negative effect on employment status, health care burden, the ability to perform activities of daily living, and health-related quality of life (HRQOL). 3, 4 Moreover, as many as 50% of patients with MS reported avoidance of social activities because of concerns about their walking speed. 5 Maintenance of walking ability has been reported by patients with MS as the most highly valued bodily function. 6 The Timed 25-Foot Walk (T25-FW) is a short-format walking test commonly used in clinical practice and is one of the components of the Multiple Sclerosis Functional Composite (MSFC), an outcome measure frequently used in clinical trials to assess disability. 7 The T25-FW is easy to administer, is useful for a range of walking disabilities, and correlates well with other measures of walking ability. 8 Evaluation of changes in walking ability is important in clinical trials and clinical practice to assess disability progression. The importance of understanding the clinical meaning of change in the T25-FW and other components of the MSFC was emphasized by an expert panel convened by the National Multiple Sclerosis Society in May 2011. 9 That panel recommended analysis of existing data to determine the feasibility of using the MSFC approach as a primary outcome measure for clinical trials in MS. The expert panel supported the use of the MSFC as a clinically meaningful outcome measure for MS clinical trials but recommended focusing on the component measures because the meaning of changes in composite z scores is not obvious, depends on the reference population, and is not comparable across studies. To this end, the task force recommended validating changes in the MSFC components in relation to known or interpretable changes in other assessments, particularly patient-reported outcome measures.
9
A clinically meaningful change is generally considered to be a change of sufficient magnitude that it is perceived by patients as being clinically important. One way to establish whether a change in a clinician-rated outcome is clinically meaningful is to determine the relationship between patientreported outcomes and change in the clinician-rated outcome. Several previous studies assessed the clinical importance in T25-FW walking time using distribution or anchor-based approaches comparing the T25-FW with patient-or clinicianassessed measures. [10] [11] [12] [13] [14] 
Methods

Clinical Trials
Descriptions of the patients and methods for the IMPACT, 20 AFFIRM, 18 and SENTINEL 19 trials have been published. Briefly, the IMPACT trial (N = 436) was a 2-year, multicenter, randomized, double-blind trial of intramuscular (IM) interferon beta1a, 60 μg administered weekly (n = 217), vs placebo (n = 219) in patients with SPMS. Enrolled patients ranged from 18 to 60 years of age, had clinically definite SPMS, and had an Expanded Disability Status Scale (EDSS) score of 3.5 to 6.5. The AFFIRM trial (N = 942) was a multicenter, randomized, doubleblind, 30-month trial of natalizumab, 300 mg every 4 weeks (n = 627), vs placebo (n = 315). Enrolled patients ranged from 18 to 50 years of age and had a diagnosis of RRMS, an EDSS score of 0 to 5.0, and at least 1 documented relapse in the 12 months before trial entry. The SENTINEL trial (N = 1171) was a multicenter, randomized, double-blind, placebo-controlled, 30-month trial of natalizumab, 300 mg every 4 weeks, plus IM interferon beta-1a, 30 μg once weekly (n = 589), vs placebo every 4 weeks plus IM interferon beta-1a, 30 μg once weekly (n = 582). Enrolled patients ranged from 18 to 55 years of age and had a diagnosis of RRMS, an EDSS score of 0 to 5.0, at least 1 documented relapse, and had received treatment with IM interferon beta-1a once weekly for at least 12 months before randomization.
Assessments
The T25-FW, as part of the MSFC, was assessed at baseline and every 3 months in the IMPACT, AFFIRM, and SENTINEL trials. The SF-36, as part of the Multiple Sclerosis Quality of Life Inventory, 22 was assessed at baseline and weeks 52 and 104 in the IMPACT trial and at baseline and weeks 24, 52, and 104 in the AFFIRM and SENTINEL trials. For the T25-FW, patients were instructed to walk as fast as they could in a safe manner along a marked 25-foot course. 23 The use of a walking aid was allowed. The time in seconds to complete each test was recorded, and the test was immediately repeated. The mean T25-FW walking time from the 2 as-with higher scores indicating better HRQOL. The SF-36 also has 2 summary scales, the Physical Component Summary (PCS) and the Mental Component Summary, with a mean score of 50 and an SD of 10 representing the reference score for the US general population. A 5-point change in PCS score is considered clinically meaningful. 24 
Statistical Analysis
Mean baseline and mean change from baseline to 2 years in T25-FW walking speed and SF-36 subscale and PCS scores were calculated. For the analyses of the relationship between T25-FW walking speed and SF-36 scores at baseline, data from all treatment groups of the 3 trials were combined and analyzed using Pearson product moment (r) and Spearman rank correlations. The same analyses were performed in patients with a baseline EDSS score of less than 4.0 and an EDSS score of 4.0 or greater. For the analyses of the relationship between percentage of change from baseline to 2 years in T25-FW walking speed and mean change from baseline to 2 years in SF-36 scores, data from the placebo groups of the IMPACT and AFFIRM trials were pooled and analyzed using the Pearson product moment and Spearman rank correlations. The percentage of change from baseline to 2 years in T25-FW walking speed in the pooled placebo group was summarized in patients with and without a 5-point worsening in PCS score. In addition, the change in PCS score from baseline to 2 years was summarized for patients with the following percentage of changes in T25-FW walking speed: improvement of more than 20% and declines of at least 0%, 5%, 10%, 15%, 20%, 25%, and 30%.
Results
Walking Speed and HRQOL at Baseline
A total of 2549 patients constituted the combined patient population from the treatment groups of the IMPACT, AFFIRM, and SENTINEL trials. Baseline MS clinical characteristics differed among the pooled treatment groups, reflecting the different eligibility criteria among the trials (eTable in the Supplement). Most notably, the mean and median EDSS scores were higher and the proportion of patients with relapses in the year before trial entry was lower in the pooled treatment groups that included patients from the IMPACT trial vs those that included patients from the AFFIRM and SENTINEL trials. The mean baseline walking speeds by treatment group are shown in 25 The mean (SD) SF-36 PCS score was 41.6 (10.5) among all patients Among all patients in the 3 trials, a significant positive correlation (r = 0.48; P < .001) was observed between baseline walking speed and baseline SF-36 PCS scores ( Figure 1 and Table 2 ). Among the SF-36 subscales, the strongest correlation was between the SF-36 Physical Functioning score and walking speed (Table 2 ). Significant correlations also were observed between baseline walking speed and SF-36 PCS and Physical Functioning scores in patients with less disability (EDSS score, <4) and more severe disability (EDSS score, ≥4) ( Table 2) .
Change in Walking Speed and HRQOL From Baseline to 2 Years
In the pooled placebo groups of the IMPACT and AFFIRM trials, the mean (SD) walking speed was 4.20 (1.87) ft/s at baseline and declined by 0.44 (0.91) ft/s at year 2. The mean (SD) SF-36 PCS score was 39.9 (10.8) at baseline and worsened by 1.0 (8.4) points at year 2 ( Table 3) . A significant correlation was observed between the change in SF-36 PCS score and the percentage of change in walking speed from baseline to 2 years in patients in the pooled placebo group (r = 0.35; P < .001). Significant correlations between the change in SF-36 PCS score to 2 years and percentage of change in walking speed also were observed in each active treatment group (r, 0.13-0.28; P ≤ .005).
Placebo-treated patients who experienced a clinically meaningful worsening (≥5-point decrease 24 [27.5%]) in SF-36 PCS score from baseline to 2 years exhibited a mean decline of 21.8% in walking speed vs a mean decline of 5.4% in those without clinically meaningful worsening in SF-36 PCS score ( Figure 2 ). When patients were grouped by incremental changes of 5% in walking speed, SF-36 PCS score declined in patients whose walking speed worsened and improved in patients who walked more than 20% faster ( Figure 3) . A decline in walking speed of 20% to 25% or more was associated with a mean decline in SF-36 PCS score of 5 points or more ( Figure 3 ).
Discussion
In this post hoc analysis of data from 2 clinical trials of patients with RRMS and 1 trial of patients with SPMS, a significant correlation was observed between walking speed and SF-36 PCS score at baseline in patients with mild and more severe disability. In placebo-treated patients, a significant cor- Downloaded From: on 10/11/2018 relation was observed between the change from baseline in SF-36 PCS score and the percentage of change in walking speed at 2 years. In placebo-treated patients, a decline in walking speed of 20% to 25% was associated with clinically meaningful worsening in SF-36 PCS scores during the 2-year period. Thus, the results from the present anchor-based analysis demonstrate that a decline in walking speed of 20% to 25% can be considered a clinically meaningful change. Previous work suggested a relationship between gait impairment and declines in HRQOL in patients with MS. Increased severity of patient-reported walking and mobility problems was associated with worsening health status assessed using the EuroQol 5-Dimension Index and the Hamburg Quality of Life Questionnaire in multiple sclerosis. 27, 28 An indirect analysis using EDSS scores as a bridge 29 showed that slower walking speed was associated with lower health utility scores in patients with MS. In addition, patient-perceived reductions in walking speed, assessed using responses to item 10 on the Multiple Sclerosis Impact Scale, were associated with reduced HRQOL as assessed using the EuroQol 5-Dimension Index and the 12-Item Short Form Health Survey. 30 To our knowledge, the present report is the first direct analysis of the relationship between objectively measured walking speed on the T25-FW and HRQOL in patients with MS.
Results to date suggest that a deterioration of 20% or more in walking time on the T25-FW is clinically meaningful. Distribution-based approaches showed that the variability of repeated testing of the T25-FW walking time was generally less than 20%. 11, 13 In anchor-based studies, a 20% or greater increase in T25-FW walking time was associated with patientreported walking difficulty, 11 and changes (worsening or improvement) of 20% or more in T25-FW walking time were Change in T25-FW walking speed was assessed from baseline to 2 years in patients in the pooled placebo group. Error bars represent SEM. Clinically meaningful worsening was defined as a decrease of 5 points or more in SF-36 PCS score from baseline to 2 years. Patients who experienced a clinically meaningful worsening in SF-36 PCS score from baseline to 2 years (n = 103) exhibited a mean decline of 21.8% in walking speed vs 5.4% in those without clinically meaningful worsening in SF-36 PCS score (n = 272). In a retrospective study of a clinical practice population of patients with primary-progressive MS, a worsening of 20% or more in T25-FW walking time was considered to be the optimal threshold for defining disease progression. 31 The findings from the current analysis add to this body of evidence and suggest that a decline of 20% or more in T25-FW walking speed represents a clinically meaningful deterioration.
The clinical significance of worsening in a clinicianderived outcome measure may differ from the clinical significance of improvement in the same measure. Several studies have examined what constitutes clinically meaningful improvements in T25-FW walking time or speed. In patients with MS treated with intravenous corticosteroids, an improvement of 20% or more in T25-FW walking time was associated with patient-perceived improvement.
14 In a separate analysis, T25-FW walking speed improved by 17% in patients considered minimally improved on the Clinician Global Impression scale after 14 weeks of treatment with prolonged-release fampridine (dalfampridine extended release in the United States and fampridine modified or sustained release in other countries). 16 More recently, a post hoc analysis of clinical trials of prolonged-release fampridine using distribution and anchorbased approaches found that clinically meaningful changes on the patient-reported Multiple Sclerosis Walking Scale were associated with an improvement of more than 20% in T25-FW walking speed across all response criteria and as little as 15% on some response criteria. 17 In the present analysis, placebotreated patients whose walking speed improved by more than 20% had a mean improvement of 3.7 points in SF-36 PCS score during 2 years ( Figure 3 ). This improvement did not meet the 5-point threshold for a clinically meaningful change in PCS score. However, the number of patients in this group was small (n = 29), which limited our ability to draw conclusions from these results. The magnitude of change that is clinically meaningful on the T25-FW may differ depending on whether the change represents improvement or worsening. The present study was a post hoc analysis and thus has limitations. The results reflect those of a pooled population of patients with RRMS and SPMS from clinical trials with selective eligibility criteria and cannot be generalized across all patients with MS encountered in clinical practice. Moreover, the study design did not allow us to determine whether differences might exist with respect to thresholds for patients with RRMS and SPMS. Although most studies support a threshold of 15% to 20% for clinically meaningful change in T25-FW walking speed, the use of a different anchor might result in a different threshold value, and the thresholds for worsening and improvement in T25-FW walking speed might differ. The T25-FW measures walking over a relatively short distance and therefore does not address other attributes such as endurance or fatigue.
The present analyses demonstrated significant correlations between T25-FW walking speed and SF-36 PCS score at baseline and between declines in these measures over time. Furthermore, results using SF-36 PCS score as the anchor demonstrated that deterioration by 20% or more in T25-FW walking speed was associated with clinically meaningful worsening in patient-reported physical health status. Correlations between longitudinal changes in T25-FW walking speed and SF-36 PCS scores were weaker, but directionally the same, in the IM interferon beta-1a or natalizumab treatment groups vs the pooled placebo group. This finding might reflect in part the slower decline with treatment, which in turn would decrease the signal-to-noise ratio and thereby reduce the strength of the correlation. However, substantial worsening on the T25-FW in patients treated with IM interferon beta-1a remained, and therefore other items in the SF-36 PCS may be affected differen- Placebo-treated patients were grouped by incremental 5% changes in T25-FW walking speed from baseline to 2 years. Error bars represent SEM. Dotted line represents the threshold for clinically meaningful change (Ն5-point decrease) in SF-36 PCS score. The SF-36 PCS score declined in patients whose walking speed worsened and improved in patients who walked more than 20% faster. A decline in walking speed of 20% to 25% or more was associated with a clinically meaningful decline in SF-36 PCS score.
tially by treatment with this agent. The reason for the differences in the magnitude of the correlations among the treatment groups deserves further exploration.
The more normal distribution of walking speed compared with walking time raises the question of whether T25-FW walking time in the MSFC should be transformed into walking speed before calculating z scores. The advisability of this approach deserves further consideration. Additional studies are needed to confirm the thresholds for clinically meaningful improvement and worsening in T25-FW walking speed in patients with RRMS and SPMS and to evaluate the effects of treatment and MS disease variables (eg, EDSS progression, relapse status) on the relationship between walking speed and HRQOL. In addition, a natural extension of this study would be to evaluate the relationship between SF-36 PCS score and the 9-hole peg test, 32 a component of the MSFC that assesses upper limb function.
Conclusions
In patients with MS, walking speed measured using the T25-FW correlated with the SF-36 PCS scores such that a decline in walking speed of 20% to 25% corresponded to a clinically meaningful worsening of SF-36 PCS scores. A 20% to 25% decline in walking speed may be a clinically meaningful threshold for defining worsening using the T25-FW in MS clinical trials and for monitoring patients in clinical settings.
